Baseline Therapeutics

Baseline Therapeutics is committed to transforming addiction care by developing next-generation, neurobiology-driven therapies that address the root biological mechanisms of substance use disorders. Their mission is to shift addiction treatment beyond symptom management — targeting the underlying brain circuits involved in craving, reward, and compulsive behaviors.

Through rigorous translational research and strategic development, Baseline is advancing novel therapeutics — including GLP-1 receptor agonist–based treatments — with the potential to reduce addictive behaviors, lower relapse risk, and offer new hope to individuals for whom existing therapies have proved insufficient.

By bridging cutting-edge neuroscience, precision medicine, and evidence-informed innovation, Baseline seeks to deliver scalable, more effective, and biologically-targeted solutions for addiction and related behavioral health disorders. In doing so, they aim to complement existing care paradigms — and reshape what recovery can look like for individuals and families affected by addiction.